Objective: The COVID-19 pandemic may affect the nonadherence rate. The primary objective of this study was to investigate adherence to treatment in patients receiving GH. In addition, potential problems with GH treatment during the pandemic were investigated.

What this study adds:
- Treatment adherence is crucial for successful treatment with growth hormone therapy.
- Nonadherence affects linear growth.
- Nonadherence rates vary widely, from 5% to 80%.
- Older age and prolonged duration of treatment with GH increase nonadherence.

What is already known on this topic?
- Treatment adherence is crucial for successful treatment with growth hormone therapy.
- Nonadherence affects linear growth.
- Nonadherence rates vary widely, from 5% to 80%.

What this study adds?
- The median age at diagnosis is lower than KIGS data.
- Poor adherence is 15% of patients.
- Poor adherence rate is higher when compared to previous Turkish study.
- The COVID-19 pandemic may affect the nonadherence.

Abstract

Objective: Treatment adherence is crucial for the success of growth hormone (GH) therapy. Reported nonadherence rates in GH treatment have varied widely. Several factors may have an impact on adherence. Apart from these factors, the global impact of the COVID-19 pandemic, including problems with hospital admission and routine follow-up of patients using GH treatment, may have additionally affected the adherence rate. The primary objective of this study was to investigate adherence to treatment in patients receiving GH. In addition, potential problems with GH treatment during the pandemic were investigated.

Materials and Methods: This was a multicenter survey study that was sent to pediatric endocrinologists in pandemic period (June 2021 - December 2021). Patient data, diagnosis, history of pituitary surgery, current GH doses, duration of GH therapy, the person administering therapy (either parent/patient), duration of missed doses, reasons for missed doses, as well as problems associated with GH therapy, and missed dose data and the causes in the recent year (after the onset of the pandemic) were queried. Treatment adherence was categorized based on missed dose rates over the past month (0 to 5%, full adherence; 5.1 to 10% moderate adherence; >10% nonadherence).

Results: The study cohort consisted of 427 cases (56.2% male) from thirteen centers. Median age of diagnosis was 8.13 (0.13 -16) years. Treatment indications were isolated GH deficiency (61.4%), multiple pituitary hormone deficiency (14%), Turner syndrome (7.5%), idiopathic GH deficiency (7.5%), small for gestational age (2.8%), and "others" (6.8%). GH therapy was administered by parents in 70% and by patients in 30%. Mean daily dose was 32.3 mcg/kg, the annual growth rate was 1.15 SDS (min -2.74, max 9.3). Overall GH adherence rate was good in 70.6%, moderate in 14.7%, and poor in 15% of the patients. The reasons for nonadherence were mainly due to forgetfulness, being afraid, inability to access medication, and/or pen problems. It was noteworthy that there was a negative effect on adherence during the COVID-19 pandemic reported by 22% of patients and the main reasons given were problems obtaining an appointment, forgetfulness, being tired, inability to access medication, and/or pen problems. There was no difference between genders in the adherence rate. Nonadherence to GH treatment decreased significantly when the patient: administered the treatment; was older; had longer duration of treatment; and during the pandemic. There was a non-significant decrease in annual growth rate as nonadherence rate increased.

Conclusion: During the COVID-19 pandemic, the poor adherence rate was 15%, and duration of GH therapy and older age were important factors. There was a negative effect on adherence during the pandemic period.

Keywords: Children, growth hormone, adherence, COVID-19, pandemic

Introduction

Treatment adherence is crucial for successful treatment with growth hormone (GH) therapy. Patient motivation and adherence to treatment may decrease over time because of several factors, including daily injections and prolonged duration of the therapy (1). Nonadherence is the leading cause of insufficient height gain in patients on GH therapy (2,3). Reported medication nonadherence rates vary widely, from 5% to...
80% depending on the method (4). A more recent systematic review reported that medication nonadherence rates varied from 7 to 71% across the included studies (1). Treatment adherence may be influenced by many factors including patient unwillingness (fear, reasons associated with injections), forgetfulness, treatment duration, low socioeconomic status, type of injector, lack of satisfaction with treatment effect, and inability to perceive the consequences of missing a dose (3,4). There is no standardized method to ensure adherence to GH therapy. Medication adherence has been investigated through GH prescription reviews, GH patient family questionnaires, serum insulin-like growth factor 1 (IGF-1) monitoring and urinary GH measurements. Despite having lower sensitivity, questionnaires are the simplest method for these types of investigations.

There was widespread disruption of routine hospital visits and monitoring of patients on GH therapy, dating from the start of the COVID-19 pandemic, with the first case reported in Türkiye on March 11, 2020. The global effect of the pandemic included widespread disruption of routine health services and interruption to patients' treatments.

The objective of this study was to investigate treatment adherence in patients on GH therapy during pandemic period through a questionnaire. This study was also designed to investigate potential therapeutic problems that might be experienced during the pandemic.

Materials and Methods

The survey was conducted by the Turkish Society for Pediatric Endocrinology and Diabetes. The authors have prepared the questionnaire via online meeting. The centers have tested it before sending it. The study questionnaire included separate items for physicians and families (Additional file). An email was sent to each member, asking them to provide the study questionnaire to all their patients on GH therapy. Patient data, date of diagnosis, age at diagnosis, age at the onset of treatment, age at last examination, parental educational attainment, monthly household income, diagnosis (isolated GH deficiency, multiple pituitary hormone deficiencies, Turner syndrome, skeletal dysplasia, small for gestational age [SGA], chronic kidney insufficiency, Prader-Willi syndrome), history of pituitary surgery, current GH dose, duration of GH therapy, person administering GH therapy (mother and/or father or patient), duration of missed doses, reasons for missed doses, problems associated with GH therapy, and missed dose data in the preceeding year (during the pandemic). The effects of the COVID-19 pandemic were queried. Treatment adherence was categorized based on reported missed dose rates over the month preceding questionnaire completion, as follows: 0 to 5% (0-1 missed doses per month) was full adherence; 5 to 10% (2 missed doses per month) was moderate adherence; and >10% (≥3 missed doses per month) was nonadherence. The growth velocity SDS calculation was made using the Baumgartner method (5). Patients who were over 18 years old or had GH treatment for less than one year were excluded.

This study was approved on June 2, 2021 (approval no. 2021-7/22) by the Ethics Committee of the Medical School of Uludağ University.

Independent scientific support for this study was provided by Pfizer Inc. (Pfizer Grant No. 675241).

Statistical Methods

The IBM SPSS, version 23 (IBM Inc., Armonk, NY, USA) were used to analyze study data. Descriptive statistics are presented as numbers and percentages for categorical variables and mean±standard deviation (SD) or median (range or interquartile range) for numerical data. Visual analytics (histograms and probability graphs and analytic methods (Kolmogorov-Smirnov or Shapiro-Wilk tests) were used to investigate normality of data set distribution. The Chi-square test was used for two, or multiple-group comparison of categorical variables, as appropriate. For non-parametric data the Mann Whitney U test was used for two-group comparisons and the Kruskal-Wallis test was used for multiple-group comparison. Spearman’s correlation coefficient test was used for analysis of correlation between non-normally distributed numerical data. A p value less than 0.05 was considered statistically significant.

Results

This study included questionnaire responses about 427 patients (56.2% males) from 13 sites. The median age at diagnosis, at the onset of the GH therapy and at study entry were 8.13 (10.3-16 years), 8.71 (5.5-16.1 years) and 12.03 (1.08-18 years) years, respectively. Treatment duration was 0 to 6 months in 8.2% (n=35), 6 to 12 months in 12.6% (n=54), 1 to 3 years in 39.6% (n=169) and more than 3 years in 39.6% (n=169) of patients. More than three quarters (77.8%) of patients were on daily GH replacement therapy and 22.7% (n=97) reported that they returned empty vials for the purpose of adherence monitoring. The monthly family income was less than the minimum wage in 22.2%, up to minimum wage x2 in 44%, from minimum wage x2 to minimum wage x4 in 23% and more than minimum wage x4 in 10.3% of the families. The training for GH injections was provided by a compny nurse (70.3%; n=300), a hospital nurse (25.1%; n=107), or a physician (4.7%; n=20). GH replacement therapy was administered by parents (299 patients; 70%), or by the patients themselves (128 patients; 30%). Indicators for GH replacement therapy included isolated GH deficiency (61.4%), congenital or acquired multiple pituitary hormone deficiency (14%), Turner syndrome (7.5%), idiopathic GH deficiency (7.5%), SGA (2.8%), and others (6.8%), the latter grouping including Noonan syndrome, skeletal dysplasia (Thanatophoric syndrome, chronic kidney insufficiency, congenital adrenal hyperplasia, Silver Russel syndrome, cystic fibrosis, distal renal tubular acidosis and hypophosphatemic rickets (see Table 1). The mean daily GH dose was 32.69 (13.8-67) mcg/kg. GH dose by diagnosis is also shown in Table 1. Overall annual growth rate was 1.15±1.37 SDS on treatment during the pandemic. The growth rate increase by diagnosis is shown in Table 1.

The analysis of the adherence to GH therapy indicated full adherence in 70.3%, moderate adherence in 14.7%, and poor adherence in 15% of patients. The reasons for missing a dose (n=193) included forgetfulness (51.8%), treatment fatigue (13.5%), running out of medication (13.5%), overnight stays (3.5%), pen cartridge problems (2.8%), infections (1.6%) and "others" (1.6%). When asked if the COVID-19 pandemic had a negative effect on adherence, 22% (n=94) of the patients/families responded that it had. In those who responded positively, the specific mechanisms by which the COVID-19 pandemic impacted their adherence are shown (Table 2).

When the data were analyzed by good, moderate, and poor adherence grouping, there was no significant intergroup differences in terms of sex, age at diagnosis, parental educational attainment, daily dose or annual growth rate. However, prolonged treatment duration, older age, and self-injection had a significant impact on the number of missed doses during the COVID-19 pandemic. Although patients who missed more doses tended to have a poorer annual growth rate, this association was not significant there was no correlation. However, there was a significant negative correlation between the decrease in the annual growth rate SDS and longer treatment duration (r=-0.202, p=0.01). Furthermore, higher rates of missing doses correlated with duration of growth hormone treatment duration (r=0.129, p<0.01, Figure 1). Missing more doses tended to be higher in a group with acquired multiple pituitary hormone deficiency and chronic kidney insufficiency (Figure 2).

When the present study (Covid Period) compared to the previous Turkish study (19), it was noted that non-adherence rate was higher (15% vs. 7.4%, Figure 3).

Discussion

This multi-center, retrospective, questionnaire-based study provided data about adherence to GH replacement therapy in a Turkish pediatric population. However, as this study was conducted during the pandemic, study data may also be interpreted in the light of the effect of the Pandemic on GH treatment adherence. The median age at diagnosis was lower than KIGS data. At the onset of GH therapy, the mean age in KIGS data was 10.7 years versus 8.7 years in the present study. The same trend was seen in GH indication subgroups with KIGS reporting diagnosis ages of 9.1 years in IGHD, 6.2 years in congenital MPHDI, 9.7 years in acquired MPHDI, 9.7 years in ISS, 6.9 years in SGA, and 9.7 years in Turner syndrome (6-8). Lower median values in all subgroups might indicate earlier diagnosis in our cohort but the data from KIGS comes from many countries and settings and is therefore extremely heterogeneous. GH replacement doses were in line with those reported in the literature (9). Results from adherence studies show wide variations due to methodological differences. Treatment adherence may be evaluated based on the number of missed injections since the last visit, or the number of missed injections per week or per month. In the present study poor
treatment adherence was defined as ≥3 missed doses per month. Treatment adherence is a major factor in the efficacy of GH replacement therapy and poor adherence will also impact treatment costs. Previous studies indicated that nonadherence might result in medication waste of up to 15% (10). Early discontinuation rates have been reported in as much as 52% of patients on GH therapy (11) but an improvement of 10% in the adherence to GH therapy has been shown to result in an increase of 1.1 cm in the annual growth rate (1). The national survey of adherence to GH therapy in New Zealand concluded that a missed dose rate of more than one per week may lead to a significant decrease in linear growth. The height velocity (HV) SDS significantly decreased in 66% of children who missed one dose per week (12).

In a trial conducted in Israel between 2004 and 2015, adherence to GH treatment was evaluated based on proportion of days covered (PDC) defined as the days covered by filled medication/ GH therapy days prescribed by physician, in 2379 patients monitored through the healthcare system. A PDC of ≥80% was defined as good adherence. The rates of good adherence gradually decreased, being 78.2% in the first year, 75.6% in the second year and 68.1% in the third year (13). In a study using data from Easypod in 1190 patients, treatment adherence was 93.7% in the first year and 70.2% in the fifth year (14). In keeping with these earlier reports, in the present study adherence rates decreased as the duration of GH therapy increased.

In a systematic review of 11 eligible studies conducted in 2022, reported 12-month adherence rates varied between 73.3% and 95.3% with a mean of 79.3% (15). In earlier studies from Turkey, Aycan et al. reported an adherence rate of 92% in a series of 689 patients (16). A Turkish multicenter study evaluated 1-year adherence rate in a series of 216 patients (17). A missed dose rate higher than 10% was classified as poor adherence. The rate of poor adherence was reported to be 2.8% in the third month, 5.1% in the sixth month and 7.4% in the twelfth month. HV SDS was found to be increased with adherence and IGF-1 levels correlated with HV and HV SDS. Adherence rates were better in male patients. No differences were found in adherence rates between the subgroups when categorized by age, socioeconomic level and conditions underlying GH treatment requirement. Treatment adherence correlated with IGF-1. In the present study, the rate of poor adherence to GH therapy was 15%, and in keeping with earlier reports, increased nonadherence rates were associated with decreased growth SDS with statistical insignificance.

The missed dose rate was higher in a group with acquired multiple pituitary hormone deficiency and chronic kidney insufficiency. It can be related to the characteristics of the diagnosis. There are many factors that will affect the growth hormone response in both acquired multiple pituitary hormone deficiency and kidney insufficiency (such as excessive medication use, surgeries, infections, and frequent hospitalizations).

Access to medication, patient and family motivation, and receipt of training may influence adherence rates (2). The response to GH therapy is influenced by several factors, mainly individual differences in response, age at diagnosis, current growth and medication dose (18). A study in 110 patients evaluated treatment adherence in the first two years. The rate of treatment adherence was 90% and there was a negative correlation between adherence and age, pretreatment growth rate and treatment duration, whereas a positive correlation was identified between the parental educational attainment and treatment adherence (19). Another factor that has been shown to negatively impact treatment adherence was a reluctance to undergo injections in adolescents, as these are largely self-administered. Treatment adherence rates were low and family support was shown to be important for adolescents requiring GH injections (20). Treatment fatigue is another reason for treatment discontinuation among patients or may lead to reductions in doses and dose frequency. Treatment fatigue is more likely to occur in older patients and patients who have longer durations of therapy (21).

Children may refuse to do the injections themselves while other factors that may influence treatment adherence include being in adolescence, treatment duration, low socioeconomic status, type of the injector used, reluctance to undergo injections, unsatisfactory treatment effect, and inability to perceive the consequences of missing a dose (22). Furthermore, needle visibility and painful injections (due to ingredients) have been reported as other issues associated with GH therapy (23). In the present study, adherence to GH therapy decreased as patient age and treatment duration increased. These findings are in keeping with earlier reports and suggest that there is still a need for novel strategies to counter these negative influences on GH treatment adherence.

Regional differences may also impact treatment adherence. A study conducted in Iran evaluated 169 patients and reported that high costs, inability to access medication, being anxious about long-term complications, treatment fatigue, unsatisfactory treatment outcome, and painful injections were the most prominent reasons for nonadherence (24). Problems associated with treatment adherence were reported in highly religious communities, based on data from a study of 2281 patients assessed through the health system records in Israel. Thus report showed ultra-religious population had higher risk for nonadherence. Besides, a low adherence rate in the subgroup of patients starting GH replacement therapy before the age of 6 months was found. Furthermore, treatment adherence got worse with increasing treatment duration (25).

In the present study, the reasons for missing a dose were mainly forgetfulness, treatment fatigue, running out of medication, overnight stays, pen cartridge problems, and infections. The last three reasons may be more influential because of the pandemic. The announcement of the Turkish Medicines and Medical Device Agency of the Ministry of Health on "Access to Chronic Disease Medication without Prescription" on March 16, 2020 allowed access to medicines in our country. In studies conducted before the pandemic, the rate of nonadherence was found to be between 8% and 10%, considering methodological differences between these studies (16,17). The COVID-19 pandemic may have played a role in the increased rate of nonadherence in the present study. Nonadherence rates were higher during the COVID-19 pandemic, with 15% being classified as poor adherence and a further 14.7% being classified as moderate adherence.

There are limited studies on the impact of COVID-19 on adherence to GH therapy. In a study conducted in Italy reported that treatment adherence was not negatively affected by changes in behavior mandated because of the pandemic (26). Treatment adherence was evaluated before and after the pandemic in a larger series from 18 countries using data recorded by the Easypod system. Adherence was evaluated by restrictions, school closures, and stay at home orders during the pandemic in 9562 patients before the pandemic and 7782 patients after the pandemic in a population of patients aged 6 to 18 years. Surprisingly, treatment adherence increased by 3% compared to the rates before the pandemic (28). Moreover, a study conducted in Saudi Arabia reported an adherence rate of 92%, in 130 patients with a mean age of 12.5 years (29).

**Strengths and Limitations**

The strengths of the study include multicenter design, standardized questionnaire and forms for physicians. Limitations include survey design with self-reporting of some data, differences between the centers in terms of diagnostic and therapeutic approaches to GH deficiency and a lack of standardization in completing the forms. Serum IGF1 levels were requested in the questionnaire. However, as the IGF1 norms and measurement methods of each center were not standardized, they were not evaluated in the results section.

**Conclusion**

The results of this study showed the age at diagnosis to be lower than previously reported. GH replacement therapy was administered to patients at appropriate doses. However, the rate of nonadherence to GH therapy was higher than previously reported in Turkish studies. In keeping with earlier reports, older age and prolonged duration of treatment with GH contributed to increased nonadherence rates while the effects of the pandemic may have contributed to overall worse adherence in this study.

**References**


<table>
<thead>
<tr>
<th>Growth Hormone Treatment Indication</th>
<th>n</th>
<th>Diagnosis Age (Median) (min-max)</th>
<th>Age of onset of the treatment (Median) (min-max)</th>
<th>Growth Hormone Doses (mcg/kg/day) (mean±SD)</th>
<th>Annual growth rate SDS (Median) (min-max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolated GH deficiency</td>
<td>262</td>
<td>9.4 (0.5-16)</td>
<td>10.15 (0.6-16)</td>
<td>31.65±6.75</td>
<td>1.16 (-2.55 - 9.4)</td>
</tr>
<tr>
<td>Multiple pituitary hormone deficiencies (congenital)</td>
<td>50</td>
<td>4.75 (0.16-15)</td>
<td>6.35 (0.3-15.2)</td>
<td>30.65±6.77</td>
<td>1.19 (-2.74 – 5.8)</td>
</tr>
<tr>
<td>Multiple pituitary hormone deficiencies (acquired)</td>
<td>10</td>
<td>8.7 (3-15.9)</td>
<td>10.95 (3.7-16.1)</td>
<td>28.5±4.17</td>
<td>0.92 (-0.11 – 3.24)</td>
</tr>
<tr>
<td>Turner syndrome</td>
<td>32</td>
<td>7.05 (0.2-13.8)</td>
<td>7.35 (1.2-14.1)</td>
<td>44.75±6.52</td>
<td>0.91 (-1.43 – 3.4)</td>
</tr>
<tr>
<td>Idiopathic GH deficiency</td>
<td>32</td>
<td>8.7 (0.58-12.9)</td>
<td>9.35 (0.83-14)</td>
<td>32.83±5.23</td>
<td>0.65 (-1.41 – 4.33)</td>
</tr>
<tr>
<td>SGA</td>
<td>12</td>
<td>7.2 (3-12.8)</td>
<td>7.2 (3-13)</td>
<td>42.5±13.12</td>
<td>1.04 (-1.22 – 5.22)</td>
</tr>
<tr>
<td>Noonan syndrome</td>
<td>9</td>
<td>7.7 (3.5-14.5)</td>
<td>7.7 (4.8-14.5)</td>
<td>35.74±5.88</td>
<td>0.89 (-0.81 – 2.03)</td>
</tr>
<tr>
<td>Skeletal dysplasia</td>
<td>7</td>
<td>6 (3.7-9.5)</td>
<td>7 (3.7-10)</td>
<td>32.19±9.17</td>
<td>0.17 (0.65 – 2.81)</td>
</tr>
<tr>
<td>Prader-Willi syndrome</td>
<td>4</td>
<td>0.92 (0.3-3)</td>
<td>1.05 (0.3-3.3)</td>
<td>22.25±8.96</td>
<td>0.10 (-2.08 – 2.7)</td>
</tr>
<tr>
<td>Chronic kidney insufficiency</td>
<td>3</td>
<td>7.1 (2.2-9.5)</td>
<td>8.08 (7.9-5)</td>
<td>253±6.66</td>
<td>0.29 (-0.63 – 0.64)</td>
</tr>
<tr>
<td>Congenital adrenal hyperplasia</td>
<td>2</td>
<td>7.85 (5-10.7)</td>
<td>7.85 (5-10.7)</td>
<td>23.4±2.21</td>
<td>0.63 (0.57 – 0.69)</td>
</tr>
<tr>
<td>Silver Russel syndrome</td>
<td>1</td>
<td>1</td>
<td>1.3</td>
<td>28</td>
<td>2.1</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>1</td>
<td>11</td>
<td>11</td>
<td>28</td>
<td>0.68</td>
</tr>
<tr>
<td>Distal renal tubular acidosis</td>
<td>1</td>
<td>7.08</td>
<td>7.08</td>
<td>7.08</td>
<td>1.89</td>
</tr>
<tr>
<td>Hypophosphatemic rickets</td>
<td>1</td>
<td>9</td>
<td>9</td>
<td>25</td>
<td>-0.04</td>
</tr>
</tbody>
</table>

Table 2: Adherence rate, nonadherence reason, and pandemic effect on adherence

<table>
<thead>
<tr>
<th>Reason of nonadherence (n=193)</th>
<th>Adherence rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forgetfulness (51.8%)</td>
<td>Good (70.3%), moderate (14.7%), poor (14.7%)</td>
</tr>
<tr>
<td>Treatment fatigue (13.5%)</td>
<td></td>
</tr>
<tr>
<td>Inability to access medication (13.8%)</td>
<td></td>
</tr>
<tr>
<td>Pen problems (2.8%)</td>
<td></td>
</tr>
<tr>
<td>Infection (1.6%)</td>
<td></td>
</tr>
<tr>
<td>Others (1.6%)</td>
<td></td>
</tr>
</tbody>
</table>

| Pandemic effect on adherence (n=94) | |
|--------------------------------------| |
| Appointment problems (38.5%)         | |
| Taking medication problems (17%)     | |
| Anxiety about going to the hospital (11.7%) | |
| COVID infection in patient or relatives (8.5%) | |
| Cessation of GH treatment by patient (4.3%) | |
Figure 1. The missed dose rate relation and duration of growth hormone treatment

Figure 2. Missed dose per month rate according to the etiology of growth hormone treatment indication
Figure 3. Comparison of GH adherence rate by category (good, moderate, poor) in the present study (Covid Period) and in a previous Turkish study which was performed before the COVID-19 pandemic (Ref.17)